Rhythm Pharmaceuticals, Inc.
RYTM
株式のランク
#3015
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
株価
$88.37
最終同期: 2026-10-19
時価総額
$6.08B
変化（1日）
2.55%
変化（1年）
-21.37%
国
US
取引 Rhythm Pharmaceuticals, Inc. (RYTM)
カテゴリー
Healthcare
Rhythm Pharmaceuticals, Inc.（RYTM）の発行済株式数
June 2026 時点の発行済株式数 68.59M
Rhythm Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 68.59M です。December 2023 の終わりには、同社は 57.67M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Rhythm Pharmaceuticals, Inc.（RYTM）の発行済株式数の履歴（2012 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 68.59M | 12.46% |
| 2024 | 61.00M | 5.76% |
| 2023 | 57.67M | 10.65% |
| 2022 | 52.12M | 5.08% |
| 2021 | 49.60M | 12.40% |
| 2020 | 44.13M | 21.15% |
| 2019 | 36.42M | 17.48% |
| 2018 | 31.00M | 15.99% |
| 2017 | 26.73M | 59.77% |
| 2016 | 16.73M | 64.07% |
| 2015 | 10.20M | 0.00% |
| 2014 | 10.20M | -79.72% |
| 2013 | 50.27M | 0.00% |
| 2012 | 50.27M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 270.16% |
US
|
|
| 396.00M | 477.32% |
US
|
|
| 478.91M | 598.20% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -9.34% |
NL
|
